Skip to main content
SpringerLink
Log in

MFL-P chemotherapy for pretreated metastatic Breast Cancer patients: A regimen with triple biochemical modulation by MTX-5FU, LV-5FU and 5FU-CDDP

Breast Cancer volume 6, pages 187–191 (1999)Cite this article

We’re sorry, something doesn't seem to be working properly.

Please try refreshing the page. If that doesn't work, please contact support so we can address the problem.

Abstract

Background

Chemotherapeutic regimens, such as cyclophosphamide+doxorubicin+5FU (CAF) or cyclophosphamide+methotrexate+5FU (CMF), are sometimes used in combination with endocrine or radiotherapy as a standard first line of treatment for recurrent or metastatic breast cancer. However, many cases are, or become, refractory to these treatments.

Methods

Twenty-one women with recurrent or metastatic breast cancer who previously underwent treatment were administered our original regimen of combination chemotherapy, MFL-P: Day 1, bolus methotrexate (MTX) 50 mg/body (median dose, 33 mg/m2; range, 29–35 mg/m2) and 4 hours later 5-fluorouracil (5FU) 750 mg/body/h (median dose, 497 mg/m2/h; range, 441–528 mg/m2/h); Days 2–3, bolus leucovorin (LV) 15 mg/body every 8 h×3; Days 2–5, 72 hours continuous 5FU 750 mg/body/24 h; Day 6, cisplatin (CDDP) 50 mg/body/h (median dose, 33 mg/m2/h; range, 29–35 mg/m2/h) with sufficient hydration. The subjects ranged in age from 26 to 63 years (mean age, 51.3 years).

Results

One complete and 9 partial responses were achieved among the 20 patients (response rate, 50%). In 1 patient, diffuse liver metastasis was not measurable. Among various metastatic sites, a higher response rate was observed especially for soft tissue lesions (skin, chest wall and lymph nodes; 9 responders among 11 lesions). On the other hand, in visceral or skeletal metastases, the response rate was poor. The adverse effects were tolerable in all patients, except for common low-grade stomatitis or anorexia.

Conclusions

MFL-P is useful as a second or third line of therapy for patients with refractory, recurrent or metastatic breast cancer with soft tissues lesions.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

USD 39.95

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Abbreviations

MTX:

Methotrexate

5FU:

5-Fluorouracil

LV:

Leucovorin

CDDP:

Cisplatin

ADR:

Doxorubicin

MFL-P:

MTX + 5FU + LV + CDDP

CAF:

Cyclophosphamide + ADR + 5FU

CMF:

Cyclophosphamide + MTX + 5FU

References

  1. Bruckner HW, Cohen J: MTX/5-FU trials in gastrointestinal and other cancer.Semin Oncol 10 (suppl 2):32–39, 1983.

    PubMed  CAS  Google Scholar 

  2. Gohdmann JJ, Macdonald JS: Chemotherapy of gastric cancer.Cancer Invest 7:39–52, 1989.

    Article  Google Scholar 

  3. Kan N, Okino T, Inoue K,et al: Evaluation of outpatient cisplatin for patients with advanced or recurrent gastric cancer; Combination with immunotherapy or other anti-cancer agents.Kiso to Rinsyou 28:833–841, 1994(in Japanese with English abstract).

    Google Scholar 

  4. Japanese Society for Cancer Therapy: General Rules for Reporting on Clinical Oncology, 1st ed, Kanehara, Tokyo, ppl-101, 1991.

    Google Scholar 

  5. Japanese Breast Cancer Society: General Rules for Clinical and Pathological Recording of Breast Cancer, 12th ed, Kanehara, Tokyo, ppl-68, 1996.

    Google Scholar 

  6. Scanlon KJ, Newman EM, Lu Y,et al: Biochemical basis for cisplatin and 5-fluorouracil synergism in human ovarian carcinoma cells.Proc Natl Acad Sci USA 83:8923–8925, 1986.

    Article  PubMed  CAS  Google Scholar 

  7. Nashimoto A, Sasaki J, Akai S,et al: Ambulatory combination chemotherapy with cisplatin and 5-fluorouracil for advanced gastric cancer patients.J Jpn Soc Cancer Ther 27:654–664, 1992.

    Google Scholar 

  8. Creagan ET, Richardson RL, Kavach JS: Pilot study of a continuous five-day intravenous infusion of etopo-side concomitant with cisplatin in selected patients with advanced cancer.J Clin Oncol 6:1197–1201, 1988.

    PubMed  CAS  Google Scholar 

  9. Lokich JJ, Ahlgren JD, Cantrell J,et al: A prospective randomized comparison of protracted infusional 5-fluorouracil with or without weekly bolus cisplatin in metastatic colorectal carcinoma; A Mid-Atlantic Oncology Program study.Cancer 67:14–19, 1991.

    Article  PubMed  CAS  Google Scholar 

  10. Suga S, Kimura K, Nagai H,et al: An evaluation of gastric cancers given UFT/CDDP chemotherapy.Gan no Rinsyou 37:929–939, 1991(in Japanese with English abstract).

    Google Scholar 

  11. Klaassen U, Wilke H, Weyhofen R,et al: Phase II study with cisplatin and paclitaxel in combination with weekly high-dose 24 h infusional 5-fluorouracil/leucovorin for first-line treatment of metastatic breast cancer.Anti-Cancer Drugs 9:203–207, 1998.

    Article  PubMed  CAS  Google Scholar 

  12. Sasaki T: Sequential methotrexate and 5-fluorouracil.Jpn J Cancer Chemother 23:1907–1910, 1996.

    CAS  Google Scholar 

  13. Oura S, Sakura T, Yoshimura G,et al: Result of biochemical modulation therapy of 5-FU with low dose cisplatin for anthracycline resistant breast carcinoma.J Jpn Soc Cancer Ther 31:957–964, 1996.

    Google Scholar 

  14. Alonso V, Santander C, Florian J,et al: Phase II trial of oral tegafur and folinic acid with mitoxantrone as first-line regimen in patients with metastatic breast cancer.Tumori 82:61–64, 1996.

    PubMed  CAS  Google Scholar 

  15. Haaz MC, Fischel JL, Forment P,et al: Impact of different fluorouracil biochemical modulators on cellular dihydropyrimidine dehydrogenase.Cancer Chemother Pharmacol 38:52–58, 1996.

    Article  PubMed  CAS  Google Scholar 

  16. Okino T, Kan N, Satoh K,et al: Therapeutic effect of sequential chemotherapy using methotrexate, 5-FU, leucovorin and cisplatin (MFLP) against advanced and/or recurrent gastric cancer. In: Siewert JR, Roder JD eds, Progress in Gastric Cancer Research 1997, Monduzzi Editore SpA, Bologna, ppl819–1823, 1997.

    Google Scholar 

  17. Platesi G, Gianni L, Manzotti C,et al: Sequence dependence of the antitumor and toxic effects of 5-fluorouracil and cis-diamminedichloroplatinum combination on primary colon tumors in mice.Cancer Chemother Pharmacol 21:237–240, 1988.

    Google Scholar 

  18. Kuroki M, Nakano S, Mitsugi K,et al:In vivo comparative therapeutic study of optimal administration of 5-fluorouracil and cisplatin using a newly established HST-1 human squamous-carcinoma cell line.Cancer Chemother Pharmacol 29:273–276, 1992.

    Article  PubMed  CAS  Google Scholar 

  19. Furukawa S, Yoshida T, Tukuda M,et al: Experimental study on combination chemotherapy with platinum compounds and 5-fluorouracil.Jpn J Cancer Chemother 16(part-I):419–422, 1989.

    CAS  Google Scholar 

  20. Esaki T, Nakano S, Matsumoto N,et al: Schedule-dependent reversion by 5-fluorouracil in a newly established cisplatin-resistent HST-1 human squamous carcinoma cell line.Int J Cancer 65:479–484, 1996.

    Article  PubMed  CAS  Google Scholar 

  21. Nakano S, Niho Y: 5-Fluorouracil and cisplatin sequential chemotherapy; Mechanism of action and clinical application in advanced, unresectable non-small cell lung cancer.Intern Med 34:288–291, 1995.

    Article  PubMed  CAS  Google Scholar 

  22. Bruckner HW, Chesser MR, Wong H,et al: Folate biochemical modulation regimen for the treatment of gastric cancer.J Clin Gastroenterol 13:384–389, 1991.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Surgery, Rakuyo Hospital, 143 Agura-cho, 606-0017, Iwakura, Sakyo-ku, Kyoto, Japan

    Norimichi Kan

  2. Department of Surgery, Saiseikai Kumamoto Hospital, Japan

    Goro Honda

Authors
  1. Norimichi Kan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Goro Honda
    View author publications

    You can also search for this author in PubMed Google Scholar

About this article

Cite this article

Kan, N., Honda, G. MFL-P chemotherapy for pretreated metastatic Breast Cancer patients: A regimen with triple biochemical modulation by MTX-5FU, LV-5FU and 5FU-CDDP. Breast Cancer 6, 187–191 (1999). https://doi.org/10.1007/BF02967166

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02967166

Key words

search

Navigation